Abstract: A low inductance capacitor with annular distributed cores is provided, which relates to the technical field of capacitors, and includes a lower bus bar, capacitor cores and an upper bus bar. Currents accessed from lower connection terminals flow to a closed end of the lower bus bar along copper bar connecting plates, and flow to the upper bus bar through the capacitor cores, and then flow out from upper connection terminals to form a loop. And positions of the copper bar connecting plates are in one-to-one correspondence with positions of the capacitor cores, and flow directions of the currents are opposite.

Abstract: A tunneling system includes a bolter miner, a bolter-integrated transportation machine, a transfer machine, a self-moving tail and a belt conveyor. The bolter miner includes a rack, a cutting device, and a bolt support device. The bolt support device includes a lifting assembly, a work platform, a first drilling frame assembly and a stabilizing assembly. The lifting assembly is arranged between the rack and the work platform. The first drilling frame assembly and the stabilizing assembly are arranged on the work platform. The bolter-integrated transportation machine is arranged behind the bolter miner and configured to transfer coal rock cut and conveyed by the bolter miner. One end of the transfer machine is connected with the bolter-integrated transportation machine, and the other end of the transfer machine is lapped with the self-moving tail. The belt conveyor is arranged behind the self-moving tail.

Abstract: A tunnel tunneling system includes a bolter miner, a bolter-integrated transportation machine, a transfer machine, a self-moving tail and a belt conveyor. The bolter miner includes a rack, a cutting device, a drilling device and a control device. The cutting device is arranged on the rack and is swingable in an up-down direction, and has a lowest swing angle and a highest swing angle. The drilling device is arranged on the rack, and includes a drilling rig and a sensor. The drilling rig is configured to drill a tunnel floor and/or a tunnel roof, and the sensor is configured to monitor a set parameter of the drilling rig and generate a monitoring data signal when the drilling rig is drilling. The control device is configured to receive and analyze the monitoring data signal.

Abstract: Disclosed herein is an optogenetics-based gene therapy that involves channelrhodopsin fusion proteins having an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS) that can effectively target the fusion protein to an inner mitochondria membrane, and a channelrhodopsin ion channel domain that can change the mitochondrial membrane potential (??m) when light is present. The disclosed optogenetics-based gene therapy system can in some embodiments further involve luciferase fusion proteins to stimulate the channelrhodopsin without reliance on external light that has an outer mitochondrial membrane-mitochondrial localization signal (OMM-MLS) that can effectively target the luciferase fusion protein to an outer mitochondrial membrane, and a luciferase protein that can produce a bioluminescence in the presence of a luciferase substrate.

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Abstract: Compounds of formula Ia and Ib wherein A, B, C, R1 and R14 are described herein.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Abstract: This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

Abstract: Compounds of formula (Ia) and (Ib), wherein A, B, C, R1and R14 are described herein.